Phanes Therapeutics
↗San Diego, California, USA
Phanes Therapeutics is a San Diego-based biotechnology company focused on the discovery and development of innovative bispecific antibodies for cancer immunotherapy. Founded in July 2016 by industry veterans from Pfizer, Amgen, and Johnson & Johnson, the company has developed proprietary technology platforms to engineer native IgG-like bispecific antibodies with enhanced stability and manufacturing characteristics. The company's primary focus is on immuno-oncology, specifically leveraging its three core platforms—PACbody™, SPECpair™, and ATACCbody™—to develop novel therapeutics that boost both innate and adaptive immunity for treating solid tumors and blood cancers.
Phanes is currently advancing three clinical-stage bispecific antibody candidates: PT886 (spevatamig), PT217 (peluntamig), and PT199 (mavrostobart), all in Phase 1/2 development for various solid tumors including pancreatic cancer, gastric cancer, small cell lung cancer, and neuroendocrine cancers. The company has established strategic partnerships with major pharmaceutical companies including Merck, Roche, Fosun Kite, and Hanmi Pharmaceuticals to advance its pipeline and expand geographic reach.
CLASSIFICATION
SIZE & FINANCIALS
Employees:11-50
Founded:2016
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$55M
Investors:Sequoia Capital China, Delos Capital Partners, DYEE Capital, Hongshan Capital Group, Volcanics Venture, K2VC
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2
Modalities:Monoclonal antibodies, Bispecific antibodies, Native IgG-like bispecific antibodies
Active Trials:3
Trial Phases:Phase 1: 3 | Phase 2: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Merck (MSD): Collaboration to study PT886 (spevatamig) in combination with KEYTRUDA (pembrolizumab) in claudin 18.2-positive gastric and GEJ cancers, Roche: Supply agreement for studying PT217 (peluntamig) in combination with atezolizumab in DLL3-expressing cancers, Fosun Kite Biotechnology: Exclusive provision of humanized antibodies for CAR-T development in China (including Hong Kong, Macau, and Taiwan) for solid tumors, Hanmi Pharmaceuticals: Agreement for development and commercialization
COMPETITION
Position:Emerging
Competitors:Cantex Pharmaceuticals, Kymera Therapeutics, Byondis, CytomX Therapeutics, Inovio Pharmaceuticals, Gliknik, Enterprise Therapeutics, Centrose +1 more
LEADERSHIP
Key Executives:
Ming Wang - Founder, President and CEO
Hui Zou - Chief Scientific Officer (CSO) and Executive Vice President
Rita Laeufle - Chief Medical Officer
Chelsea Johnson - Senior Director, Clinical Science and Operations
Paul Chu - Vice President Business Development
Scientific Founders:Ming Wang
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Phanes Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.